Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDH1 peptide vaccine + temozolomide
- Development stage
- Unknown
- Lead developer
- Duke University Medical Center
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Peptides, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination therapy consisting of an isocitrate dehydrogenase 1 (IDH1) R132H mutation-specific peptide vaccine and the alkylating chemotherapy agent temozolomide. The IDH1 peptide vaccine is designed to stimulate an immune response specifically against tumor cells expressing the mutant IDH1 protein, which is a hallmark of many low-grade gliomas. The mechanism involves induction of T cell responses targeting the neoepitope created by the R132H mutation in IDH1, leading to anti-tumor immunity. Temozolomide acts as a DNA alkylating agent that induces cytotoxicity in dividing tumor cells and may also enhance immunogenicity by increasing antigen presentation or modulating the tumor microenvironment. This combination has been investigated primarily for recurrent grade II glioma with confirmed mutant IDH1 status, aiming to improve immune-mediated tumor control alongside standard chemotherapy[2][5][6].
- Other names
- mutant IDH1 peptide vaccine + temozolomideIDH1(R132H) peptide vaccine + temozolomide
02
Targets
N7-G (DNA guanine-N7 adduct)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on IDH1 peptide vaccine + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDH1 peptide vaccine + temozolomide.